Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
Catharina BuschSamantha Fraser-BellMatias IglickiMarco LupidiAude CouturierVoraporn ChaikitmongkolErmete GiancipoliPatricio J Rodríguez-ValdésPierre-Henry GabrielleInês LaínsAna Rita SantosZafer CebeciAtchara AmphornphruetValentin DegenhardtJan-Darius UnterlauftCarlo CaginiValérie Mané-TautyGiuseppe D'Amico RicciIsaac HindiKushal AgrawalJay ChhablaniAnat LoewensteinDinah ZurMatus Rehaknull nullPublished in: Acta diabetologica (2019)
The beneficial effect of an early switch to DEX implant in DME non-responders seen at month 12 was maintained during the second year. A later switch from anti-VEGF to steroids still provided significant improvement. Eyes continued on anti-VEGF over a period of 24 months maintained vision. A quarter of eyes, which had not improved vision at 12 months, exhibited a delayed response to treatment.